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Background: Pancreatoduodenectomy is one of the most complex abdominal operations, usually performed for
tumors of the periampullary region and chronic pancreatitis. Leakage of pancreatic juice from the pancreatoenteric
anastomosis, called postoperative pancreatic fistula, is the most prominent postoperative complication.
Retrospective studies show a significant reduction of fistula rates with pancreatogastrostomy as compared to
pancreatojejunostomy, the most frequently employed method of pancreatoenterostomy. Most single-center
prospective trials, however, have not validated this finding. A large multicenter trial is needed for clarification.
Methods/design: RECOPANC is a prospective, randomized, controlled multicenter trial with two treatment arms,
pancreatogastrostomy versus pancreatojejunostomy. The trial hypothesis is that postoperative pancreatic fistula rate
is lower after pancreatogastrostomy when compared to pancreatojejunostomy. Fourteen academic centers for
pancreatic surgery will participate to allocate 360 patients to the trial. The duration of the entire trial is four years
including prearrangement and analyses.
Discussion: Postoperative pancreatic fistula is the main reason for clinically important postoperative morbidity after
pancreatoduodenectomy. The primary goal of the chosen reconstruction technique for pancreatoenteric
anastomosis is to minimize postoperative fistula rate. A randomized trial performed at multiple high-volume centers
for pancreatic surgery is the best opportunity to investigate one of the most crucial issues in pancreatic surgery.
Trial registration: German Clinical Trials Register DRKS00000767 (2011/03/23), FSI 2011/05/31. Universal Trial
Number U1111-1117-9588.
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Trial rationale
Pancreatoduodenectomy (PD) is one of the most complex
abdominal operations, involving removal of the head of
pancreas, duodenum and common bile duct. It is usually
performed for removal of tumors of the periampullary
region and for treatment of complications and pain in
chronic pancreatitis. Today this operation can be performed
with mortality rates below 5% at specialized centers, but
perioperative morbidity remains high [1,2]. Since the begin-
ning of pancreatic surgery [3], one of the most frequently
encountered complications is leakage of pancreatic juice
from the pancreatoenteric anastomosis, so-called post-
operative pancreatic fistula (POPF) [4]. Depending on
severity, POPF may lead to the prolongation of the hospital
stay for specific treatment or even severe secondary compli-
cations. Reported rates of POPF after PD are between 20%
and 30% in recent series [5,6]. The most important risk fac-
tor for development of POPF is a healthy, non-fibrotic pan-
creas with normal exocrine function that is found to be
‘soft’ on intraoperative palpation [7].
Many different methods of anastomosis that aim to
reduce POPF rate have been described. The two main tech-
niques practiced today are pancreatojejunostomy (PJ) and
pancreatogastrostomy (PG), and for each one several sub-
types have been invented [8,9].
Almost all retrospective studies comparing PG and PJ
have reported a reduced POPF rate with PG, leading to a
clinically important reduced POPF rate in meta-analysis
[10,11]. However, three randomized controlled trials (RCTs)
[12-14] did not validate this finding on meta-analysis. Only
the most recent RCT of PG versus PJ showed a significant
reduction in POPF rate with PG [15]; however, this trial has
not yet been included in a meta-analysis. All RCTs reported
so far show certain limitations; one of which is that defini-
tions for POPF vary and are different from the currently
accepted International Study Group of Pancreatic Surgery
(ISGPS) definition. The only multicenter trial included in
the meta-analysis showed a strong center effect and one
single-center trial only included patients with a soft pan-
creas and small pancreatic duct. Two trials used intraopera-
tive randomization, which may lead to a selection bias. The
latest trial used a special technique of PG with gastric parti-
tioning. In summary, generalizability of results is limited.
Furthermore, the total case number in previous RCTs of
around 150 provides a relatively low statistical power for
detection of a difference in POPF rates.
Aim
The objective of the RECOPANC trial is to compare the
rate of POPF after PG and PJ. It is expected that POPF
rates are lower with PG. There is no restriction regarding
the particular technique of PG or PJ, ensuring that results
may be generalized. To achieve a high case number andprovide a high standard of surgical expertise, the trial is
performed as a multicenter trial of specialized centers.
Methods/design
Trial design
RECOPANC is designed as a prospective, randomized,
observer- and patient-blinded, controlled multicenter trial
with two parallel study arms. The trial interventions are
reconstruction of the pancreatoenterostomy by PG and by
PJ, with the latter constituting the control intervention.
Various techniques of PG and PJ have been described, dif-
fering in certain details (end-to-end or end-to-side PJ, with
or without invagination or pancreatic duct stenting, single-
layer or duct-mucosa anastomosis, technique of the asso-
ciated gastro- and hepaticoenterostomy [9]). To achieve
generalizable results for this trial, there is no restriction con-
cerning the particular technique of PG or PJ.
Inclusion criteria are elective PD, age of at least 18 years
and given written informed consent. Exclusion criteria are
participation in another intervention-trial with interference
of intervention and outcome and expected lack of com-
pliance by the patient.
Recruitment and timeline
At least 14 trial centers are going to participate in the
RECOPANC trial. Recruitment will be performed pre-
operatively at the respective trial centers by the attending
physicians. The time from first patient in to last patient
out is planned from June 2011 to May 2014, including
two years of subject recruitment followed by one year of
follow-up. The duration of the entire trial is four years in-
cluding prearrangement and analysis. The actual overall
duration or recruitment time may differ.
Randomization
To achieve comparable intervention groups, patient allo-
cation will be concealed by preoperative randomization
on the day of surgery using a centralized web-based tool
(Randomizer Software, Institute for Medical Informatics,
Statistics and Documentation of the Medical University
of Graz, www.randomizer.at). Block randomization will
be performed for each center to achieve equal group
sizes per center. The randomization number is generated
by the centralized web-based tool.
Blinding
At each trial center, there will be a blinded assessor who
evaluates the outcome of the trial in terms of primary
endpoint. The case report form (CRF) documents only
whether pancreatoenterostomy was performed according
to randomization. This information can be obtained from
the surgeon, who cannot be blinded. Patients are kept
blinded and unblinding of patients is possible if necessary
for emergency treatment.
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A primary endpoint of POPF of grade B or C has been
chosen because it is usually regarded as the most important
problem in pancreatic surgery. In the past, many different
definitions of POPF have been used. The ISGPS introduced
an international consensus definition in 2004, which
includes a severity grading (grade A, B, C) [4]. As it has
been shown that grade A POPF has virtually no impact on
patient care and health care costs [5], we have chosen
POPF grade B or C as the primary endpoint for this trial.
The ISGPS definition and ‘POPF grade B or C’ have been
used as an endpoint in several retrospective studies and
also in current prospective randomized trials of pancreatic
surgery [15,16]. Recently, detailed criteria have been pub-
lished [17] as a guide to interpret the original definitions of
POPF grades according to the ISGPS. These will be
adhered to in the current study with one modification:
application of somatostatin analogues will not lead to classi-
fication as POPF grade B or C, because somatostatin analo-
gues are applied routinely in some centers and its effect on
the reduction of pancreatic fistula risk is questionable [18].
POPF of grade B or C according to the ISGPS definition
constitutes a dichotomous (yes or no) endpoint. POPF is
present by definition if, on or after postoperative day 3, total
amylase activity in the peritoneal drain secretion exceeds
the upper normal limit of serum amylase activity threefold.
POPF is of grade A when grade B or C criteria are not ful-
filled. The scorers of each study center are trained during
the trial initiation visit by the monitors; extensive monitor-
ing during the trial will ensure the reliability of outcome
assessment.
Secondary endpoints
Secondary endpoints are assessed to cover other important
aspects of outcome after PD and thereby achieve a valid
comparison between the two study arms. The secondary
endpoints comprise two main fields. First, the most typical
problems or complications of pancreatic surgery are
included as perioperative secondary endpoints. To ensure
comparability and generalizability of results, existent
ISGPS definitions are employed here, too.
Second, long-term outcomes regarding pancreatic
function and quality of life are considered. We chose
30 days, 6 months and 12 months as time points for
long-term outcome evaluation visits, to ensure inclusion
of oncological patients in the follow-up, where survival
time is limited. Quality of life is measured by use of the
well-established European Organisation for Research and
Treatment of Cancer (EORTC) Quality of Life Question-
naire (QLQ)-C30 and QLQ-PAN26 (for pancreatic cancer)
(EORTC Study Group on Quality of Life, Brussels,
Belgium). Long-term pancreatic function is an often
neglected aspect in surgical technical studies. In this trial,
we assess pancreatic function by a questionnaire (includedin the CRF) regarding the necessity of antidiabetic medica-
tion, pancreatic enzyme supplementation and symptoms
of exocrine pancreatic insufficiency. More objective assess-
ment of pancreatic function (oral glucose tolerance test,
pancreatic secretion samplings or stool enzyme activity
measurements) is not planned to date. According to our
own experience, it cannot be expected that these time-
consuming and expensive analyses will be performed in
the majority of patients enrolled in the trial at various
centers in our multicenter trial.
Definitions of secondary endpoints are:
 overall mortality: death due to any cause at any time
during follow-up period
 POPF, grade A (ISGPS definition [4], yes or no)
 delayed gastric emptying of grade B or C (ISGPS
definition [19], yes or no)
 postpancreatectomy hemorrhage (ISGPS definition
[20], yes or no)
 intra-abdominal fluid collection or abscess requiring
invasive treatment (yes or no)
 relaparotomy (yes or no)
 necessity of completion total pancreatectomy (yes
or no)
 anastomotic leak other than POPF (yes or no)
 wound infection requiring invasive treatment (yes
or no)
 septic shock: sepsis requiring catecholamine
treatment (yes or no)
 respiratory failure requiring invasive mechanical
ventilation (yes or no)
 deep venous thrombosis (yes or no)
 lung embolism (yes or no)
 myocardial infarction (yes or no)
 stroke (yes or no)
 operation time from incision to end of skin closure
(minutes)
 postoperative hospital stay until discharge (days)
 learning curve effects
 pancreatic endocrine and exocrine function
(steatorrhea, necessity of oral enzyme replacement,
necessity of antidiabetic or insulin therapy)
 quality of life (EORTC QLQ-C30 and QLQ-PAN26,
according to the scoring manual published by the
EORTC Quality of Life group [21])
Trial locations
To achieve the highest standard of care and avoid center
bias, only high-volume academic centers for pancreatic sur-
gery are selected to participate in the trial. Minimum
requirements for inclusion are at least five pancreatic head
resections with each of the two reconstruction techniques
(PG and PJ) per year or previous experience with at least 25
pancreatoduodenectomies of each technique. Participating
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tationschirurgie Universitätsklinikum Aachen; Klinik für
Allgemein-, Viszeral- und Transplantationschirurgie Charité
Campus Virchow; St. Josefs-Hospital Bochum; Klinik
und Poliklinik für Allgemein-, Viszeral-, Thorax- und
Gefäßchirurgie Universitätsklinikum Bonn; Klinik für Allge-
mein- und Viszeralchirurgie Universitätsklinikum Freiburg;
Klinik für Allgemein-, Viszeral-, Thorax-, Transplantations-
und Kinderchirurgie Universitätsklinikum Giessen; Klinik
und Poliklinik für Allgemein-, Viszeral- und Thoraxchir-
urgie Universitätsklinikum Hamburg-Eppendorf; Klinik
für Allgemein-, Viszeral- und Transplantationschirurgie
Universitätsklinikum Heidelberg; Chirurgische Klinik
Universitätsklinikum Mannheim; Klinik für Viszeral-
Thorax- und Gefäßchirurgie Universitätsklinikum Marburg;
Chirurgische Klinik und Poliklinik Universitätsklinikum
München LMU; Klinik für Viszeral- Thorax- und
Gefäßchirurgie Klinikum Rechts der Isar München; Allge-
mein- und Viszeralchirurgie Krankenhaus Barmherzige
Brüder Regensburg; and Klinik und Poliklinik für Chirurgie




The prior assumption is an overall rate of pancreatic fistula
type B or C within 30 days after surgery in the PG group of
6% (5/82 patients) versus 16% (14/84 patients) in the PJ
group. The sample size calculation is based on the primary
outcome - POPF grade B or C, as reported in the rando-
mized trials by Fernandez-Cruz et al. [15] and Wellner
et al. [22]. With alpha = 5% and beta = 20%, a sample size
of n = 153 per group is necessary to detect a difference
between the intervention groups when applying the Chi-
square test (two-sided analysis, SAS 9.1 software, SAS, Cary,
NC, USA). It can be expected that including covariates of
prognostic importance [7] in the logistic regression model
applied in confirmatory analysis will increase the power as
compared to the Chi-square test [23]. To address the uncer-
tainty in the estimation of the rates of pancreatic fistula in
the two intervention arms, an adaptive interim analysis is
planned according to Bauer and Köhne [24] after re-
cruitment of half of the necessary participants (n = 152).
Assuming a drop-out rate of 15%, another 54 patients
have to be randomized for a total of n = 360 patients to
be allocated to this trial. It is estimated that around 400
patients will have to be assessed for eligibility. Loss to
follow-up is expected to be marginal: during the period
that the primary endpoint (POPF grade B or C) has to
be assessed (until postoperative day 30), all patients are
under continuous in-hospital observation in the peri-
operative period, followed by in-hospital rehabilitation
for the great majority and close ambulatory observation
in every case. Previous multicenter trials in pancreaticsurgery support this assumption [13,16]. For the same
reason, the number of subjects to be excluded from final
analysis of the primary endpoint up to postoperative day
30 is estimated to be marginal. If missing values occur,
they will be replaced by the imputed case analysis in-
corporating available reasons for missing data method
described by Higgins et al. [25]. The resulting trial flow
chart is shown in Figure 1.
Analysis
The primary hypothesis is that the rate of clinically relevant
POPF (Grade B or C) is lower with PG than PJ in patients
undergoing partial PD. The analysis will be performed
according to the standard (non-modified) intention to treat
principle [26,27]. A multivariable logistic regression model
will be applied for the intervention comparison of the
POPF rates adjusting for age, center, surgeons experience
and texture of pancreatic tissue. To address the differences
already seen in the rates of POPF, an interim analysis will
be conducted after recruitment of half of the necessary case
numbers according to the design described by Bauer and
Köhne [24]. Patients with a soft pancreas have a higher risk
of developing POPF and constitute a high-risk subpopula-
tion. These patients are expected to comprise about half of
all cases [7]. If the POPF rate after PG or PJ is different in
this subgroup, it will be evaluated by an exploratory sub-
group analysis including statistical testing for interaction
with treatment [23]. SAS software version 9.1 or higher will
be used for the statistical analyses.
Withdrawals
Patients are free to leave the trial at any time and without
giving reasons for their decision. Patients may be with-
drawn from the trial at their own request; if, in the investi-
gator’s opinion, continuation of the trial may be
detrimental to the patient’s well-being; or if a PD was not
performed (because of technical unresectability, metastatic
disease or other reasons). The investigator decides on
withdrawal of subjects from the clinical trial in the case of
the latter criteria. In all cases, the reason for withdrawal
must be recorded in the CRF and in the patient’s medical
records. The patient must be followed up as far as possible;
all examinations scheduled for the final trial day must be
performed on all patients and documented. To do so the
consent of the patient is necessary and will be requested.
Stopping rules
As described in detail by Wassmer [28], in a two-stage
Bauer-Köhne design [24] addressing a two-sided problem,
it is valid to perform two one-sided tests to the level α/2.
The critical values for the smaller of the two one-sided
P-values for the primary endpoint in stage one are
α1=0.0038. Where P >0.0038, the trial will be continued
and the sample size will be recalculated. The recalculated
Figure 1 Trial flow chart.
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Safety Monitoring Board (DSMB) with the interim report.
This board will give advice whether and how additional re-
cruitment of patients will be feasible.
Premature closure
The trial may be prematurely closed by the principal in-
vestigator in consultation with the steering committee
and the responsible biometrician. If termination of thetrial becomes necessary, the RECOPANC steering com-
mittee will discuss this issue with the independent
DSMB. Reasons that may necessitate termination of the
trial include the rate or severity of serious adverse events
or morbidity in the trial indicating a potential health
hazard caused by the study treatment; patients’ enrol-
ment is unsatisfactory with respect to quality or quan-
tity; data recording is severely inaccurate or incomplete;
or external evidence demands a termination of the trial.
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Funding
The trial will be financed by funding from the Deutsche
Forschungsgemeinschaft (DFG; German Research Foun-
dation/Project number HO810/3-1).
Monitoring
Clinical monitoring will be performed by the Studienzen-
trum Freiburg, an institution which is independent from
other trial staff. Monitoring procedures will be adapted to
the study-specific risks for patients, interpretation of the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use-Good Clinical Practice (GCP) E6 guidelines
[29] and standard operating procedures of the Studienzen-
trum Freiburg to ensure patient safety and integrity of the
clinical data, for example, primary endpoint in adherence
to the study protocol. Monitor visits are taking place
before, during and after the study. Prior to study start, all
participating centers will be personally trained and intro-
duced to all study-specific procedures during individual
on-site initiation visits. Regular on-site monitoring visits
are planned at all sites depending on the recruitment rate
and quality of the data.
Data management
Central data collection and maintenance is performed by
the Institute of Medical Biometry and Informatics (IMBI),
Heidelberg, Germany. All protocol-required information for
the clinical data collected during the trial must be entered
by the investigator, or a designated representative, in the
electronic CRF. Macro™ electronic data capture software
(InferMed, London, UK [30]) will be used for electronic
CRF coding and data management. The completeness, val-
idity and plausibility of the data (clinical and quality of life
data) are examined by validating programs, which thereby
generate queries. The investigator or the designated repre-
sentatives are obliged to clarify or explain the queries. If no
further corrections are to be made in the database it will be
declared closed and used for statistical analysis.
Ethical considerations
Risks
There are no apparent risks for patients taking part in
the study as they receive the usual, standard treatments
and standard diagnostic assessment.
Informed consent
Patients will be enrolled into the study only after com-
prehensive information has been explained to them in
an understandable way by the responsible investigator,
concerning the nature, scope and possible consequences
of the clinical trial. Written informed consent for thestudy will be obtained from each patient before any
study-specific procedure and randomization is executed.
Safety and serious adverse events
Analysis of safety-related data is performed with respect to
the frequency of serious adverse events in both treatment
groups, the frequency of serious adverse events stratified by
causality and the frequency of morbidity in both treatment
groups. All serious adverse events that occur during the
trial - from randomization to the regular end of the trial at
12 months follow-up or until premature withdrawal of the
patient - must be documented on a Serious Adverse Event
Form available in the investigator site file. Serious adverse
events have to be reported by the attending physician to the
Clinical Trials Unit Freiburg within five days of the serious
adverse event becoming known.
Data safety monitoring board
An independent DSMB is established, consisting of two
academic surgeons and a biometrician. In case of any ir-
regularities, for example concerning the frequency or type
of serious adverse event reported, the principal investigator
will inform the members of the independent DSMB with-
out delay. At least once every 12 months, the DSMB will
receive a written safety report. The members of the DSMB
then report the result of the benefit and risk assessment to
the principal investigator and will give recommendations
concerning the continuation of the trial.
Approval
Before the start of the trial, the trial protocol, informed
consent document, and any other appropriate documents
will be submitted to an independent ethics committee.
The protocol has been approved by the ethics committee
of the medical faculty Freiburg and must be approved by
the ethics committees of all other participating centers
before patient recruitment is started. All amendments will
also be submitted to the independent ethics committees.
Good clinical practice
The procedures set out in this trial protocol, pertaining
to the conduct, evaluation and documentation of this
trial, are designed to ensure that all persons involved in
the trial abide by GCP and the ethical principles
described in the current revision of the Declaration of
Helsinki [31]. The trial will be carried out in accordance
with local legal and regulatory requirements.
Registration
The RECOPANC trial has been assigned a universal
trial number (UTN: U1111-1117-9588) and registered
in the German Clinical Trials Register (DRKS-ID:
DRKS00000767) as of 23 March 2011. The first patient
was randomized on 31 May 2011.
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About one hundred years after the first successful PD
was performed by Walther C.E. Kausch [3], this complex
operation can be performed routinely and with low mor-
tality at centers for pancreatic surgery. One of the main
problems contributing to a high postoperative morbidity
remains the occurrence of POPF.
Three of four randomized trials have not supported
the conclusion of numerous retrospective studies sug-
gesting a reduced POPF rate with PG when compared to
PJ. The RECOPANC trial is designed to show a signifi-
cant reduction of POPF with PG. Noteworthy features in
comparison to previous trials include a large sample size
and adaptive interim analysis for recalculation of sample
size, ensuring high statistical power; planned analysis of
the high-risk subgroup of patients with a soft pancreas;
no restriction in terms of sub-techniques of PG and PJ
and a multicenter approach, leading to generalizable
results; use of the ISGPS definitions for primary and
secondary endpoints, which makes results comparable
to other studies; and inclusion of high-volume academic
centers only, ensuring highest standard of care.
It is our aim that this trial will help to minimize post-
operative complication rates of PD.
Trial status
At the time of manuscript submission, the RECOPANC
trial is recruiting patients. The first subject was randomized
on 31 May 2011.
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